INMUNE BIO INC. - COMMON STOCK

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

08 May 2025 16:20:03 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

05 May 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

16 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

14 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

01 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

27 Mar 2025 16:05:56 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

24 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

12 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

10 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

28 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

10 Dec 2024 08:00:01 By Nasdaq GlobeNewswire

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

04 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

13 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

31 Oct 2024 16:05:51 By Nasdaq GlobeNewswire

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

28 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

24 Oct 2024 15:03:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

24 Oct 2024 09:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

11 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire